
(Reuters) - French drugmaker Sanofi SA gained U.S. approval for its multiple sclerosis pill, Aubagio, on Wednesday -- one of the two MS treatments it is relying on to return to growth after several blockbuster drugs lost patent protection. The drug has milder side effects than rival MS drugs and analysts say it could find favor among newly diagnosed patients. Around 35 percent to 40 percent of MS patients prefer to take no medication rather than face unwanted side effects. ...
Read the full article...
(From Yahoo Diseases)